Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Temozolamide and Capecitabine
Temozolamide and Capecitabine
Routinely available
Local application
02/02/2022
Indication
For inoperable pancreatic neuroendocrine tumours.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local or regional guidance
Formulation
Temozolamide oral capsules and Capecitabine oral tablets
Comments
February 2022 - Routinely available in line with local prescribing guidance. Included on the ERF for Specialist use only.